Tilray, Inc. (NASDAQ: TLRY) was established in January 2018. Prior to that, the company operated as a Dutch private limited liability company Decatur Holdings, BV. The latter was established in March 2016. After this IPO, Tilray , Inc. will operate as the latter’s holding company and is the sole holder of the latter’s assets. The company is headquartered in BC, Canada, and has 330 full-time employees (6/4/2018). It is a company that operates in Australia, Canada and The German subsidiary has used agreements with mature drug distributors to provide high-quality cannabis products to tens of thousands of patients in 10 countries on five continents, and is a company that produces medical cannabis in Canada and Europe.
Tilray, Inc. (TLRY):
Tilray, Inc. is a subsidiary of Privateer Holdings, one of the first private investment companies backed by institutions focused on the cannabis industry. Privateer Holdings’ cannabis brand portfolio also includes Leafly, Marley Natural and Goodship.
Tilray, Inc. is pioneering the future of global medical marijuana research, cultivation, processing and distribution. The company is committed to becoming a leader in the Canadian adult marijuana market after the legalization of marijuana (already legal). Tilray hopes to lead, legalize and define the future of the cannabis industry by establishing the most trusted cannabis company in the world.
Tilray, Inc., through the company’s subsidiaries in Australia, Canada and Germany, and through agreements with mature drug distributors, provides high-quality cannabis products to tens of thousands of patients in 10 countries on five continents, and produces medical products in Canada and Europe marijuana.
Tilray has been an early leader in the development of the global medical cannabis market. The company was one of the first companies to obtain a license from Health Canada to cultivate and sell medical marijuana in Canada, and one of the first companies to become a Canadian medical marijuana licensed distributor. At present, the cannabis industry is expanding rapidly in Canada. More than 100 companies have obtained licenses, but only a few companies are earlier than Tilray, and Health Canada is processing hundreds of license applications. Currently, Tilray’s products are sold in Argentina, Australia, Canada, Chile, Croatia, Cyprus, Czech Republic, Germany, New Zealand and South Africa.
Although there are currently other countries that license the cultivation and sale of medical cannabis, including some companies obtaining cannabis cultivation licenses in Canada, and other non-marijuana companies expanding into the cannabis market, Tilray, Inc. is the first legally exporting medical cannabis from North America to Africa, Companies from Australia, Europe and South America, Tilray is also one of the first companies approved to cultivate and process medical cannabis in Canada and Portugal.
Tilray, Inc. hopes to have a competitive advantage in the Canadian adult-use market and is waiting for the passage of the proposed federal legislation and corresponding provincial legislation. It is expected that Canada will legalize adult cannabis throughout the country in 2018.
Tilray, Inc. (TLRY) investment:
Tilray, Inc. (NASDAQ:TLRY) submitted its IPO prospectus on 6/20/2018 and listed on Nasdaq on 7/19/2018. The planned issue price is $14.00-$16.00, the actual issue price is $17, and the issue is 9 million. Stocks, raised 153 million US dollars, Cowen and Company lead underwriting, Roth Capital Partners/ Northland Securities joint underwriting.